Related Experiment Video
Updated: Apr 28, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
12.0K
Postprandial reactive hypoglycaemia in a very old patient
Acta Clinica Belgica
|June 12, 2014
Summary
Postprandial reactive hypoglycaemia (PRH) is challenging to diagnose. Acarbose, combined with nutritional education, effectively prevents severe hypoglycaemic events in older adults.
Area of Science:
- Endocrinology
- Geriatrics
- Clinical Medicine
Background:
- Postprandial reactive hypoglycaemia (PRH) presents diagnostic challenges due to atypical symptoms and low prevalence, particularly in the elderly.
- PRH is characterized by recurrent symptomatic hypoglycaemia in the postprandial period.
Observation:
- A case study detailing the diagnostic work-up of severe hypoglycaemic episodes in a very elderly patient diagnosed with PRH.
- The patient experienced recurrent severe hypoglycaemic episodes.
Findings:
- Acarbose, an alpha-glucosidase inhibitor, was prescribed, leading to the prevention of further hypoglycaemic episodes over a four-year follow-up.
- Nutritional education is identified as a cornerstone of PRH management.
Implications:
- Acarbose is a valuable therapeutic option for managing PRH, complementing nutritional strategies.
- This case highlights the importance of considering PRH in elderly patients with unexplained hypoglycaemic episodes.
Related Concept Videos
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:26Hypoglycemia
29
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
29
01:29Hyperglycemia
24
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
24
01:06Oral Hypoglycemic Agents: Glinides
1.0K
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
14
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
14